Here’s what you should know.
1. Providers reported two adverse events. The first involved the balloons over-inflating with air or fluid in a patient’s stomach. The second involved patients developing acute pancreatitis. Both events result in premature device removal.
2. The FDA received reports about the ReShape Integrated Dual Balloon System and the Orbera Intragastric Balloon System, both FDA-approved devices.
3. The agency recommends providers familiarize themselves over inflated balloons symptoms and perform confirmatory diagnostic studies as needed.
The FDA also recommends following manufacturer’s instructions regarding device returns or evaluations and reporting any adverse events.
4. The FDA will continue working with the manufacturers to get to the problem’s root.
More articles on gastroenterology:
Allergan expects solid 2017 under Trump administration; Takeda faces antirust suit & more —3 GI companies making waves
GI leader to know: Dr. Brij Dewan of Kalamazoo Gastroenterology
Pediatric irritable bowel syndrome patients often low in vitamin D: 4 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.